Bevatas 400

Name: Bevatas 400
Brand: Ezan Pharmaceuticals
Price: 10000 INR
Availability: InStock

Price 10000 INR/ Unit

Get a Price/Quote

MOQ : 1 Pack

Bevatas 400 Specification

Life Span
24 months from the date of manufacture

Salt Composition
Bevacizumab 400 mg/16 ml

Indication
Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma, Ovarian Cancer, Cervical Cancer

Packaging Type
Single Use Glass Vial

Brand Name
As per manufacturer (refer to packaging)

Dosage Form
Infusion (to be diluted)

Origin of Medicine
Imported/Indian (varies by supplier)

Pacakaging (Quantity Per Box)
1 vial per box

Drug Type
Other

Ingredients
Bevacizumab

Physical Form
Other

Function
Other

Recommended For
Cancer treatment (Colorectal, Lung, Glioblastoma, Kidney, Ovarian, Cervical Cancer, etc.)

Dosage
As prescribed by the physician

Dosage Guidelines
Administer as an intravenous infusion after dilution

Suitable For
Adults

Quantity
16 ml

Storage Instructions
Store at 2C to 8C. Do not freeze. Protect from light.

Appearance
Clear to slightly opalescent, colorless to pale brown solution

Regulatory Approval
WHO-GMP/US-FDA/EMA compliant (as applicable)

Concentration
25 mg/ml

Container Material
Type I glass vial with rubber stopper and flip-off cap

Compatibility
Do not mix or dilute with glucose solutions

Preservative
Preservative-free

Strength
400 mg per vial

Vial Type
Single Use Only

Route of Administration
Intravenous (IV) infusion

STERILITY
Sterile, Non-pyrogenic, Non-toxic

Diluent
Dilute with 0.9% Sodium Chloride Injection, USP

Bevatas 400 Trade Information

Minimum Order Quantity
1 Pack

Payment Terms
Cash in Advance (CID)

Supply Ability
5000 Packs Per Month

Delivery Time
10 Days

Main Domestic Market
All India, Tripura, Manipur, Arunachal Pradesh, Nagaland, Meghalaya, Assam, Mizoram

About Bevatas 400

Experience a transcendent therapy with Bevacizumab Concentrate for Solution for Infusion 400 mg/16 ml-now available at a reduced price and subject to hot deal scarcity! This world-class anti-cancer monoclonal antibody inhibits angiogenesis, boldly targeting metastatic colorectal, lung, glioblastoma, kidney, ovarian, and cervical cancers. Each valorous, single-use Type I glass vial delivers a sterile, preservative-free infusion-clear to slightly opalescent in appearance-for adult intravenous administration after dilution with sodium chloride. WHO-GMP/US-FDA/EMA compliant, and non-toxic, making it an unmatched choice for medical professionals seeking optimal patient care.

Primary Uses, Advantages, and Application Scope

Bevacizumab Concentrate for Solution for Infusion 400 mg/16 ml is primarily prescribed for the treatment of various advanced-stage cancers, including metastatic colorectal, non-small cell lung, renal cell carcinoma, glioblastoma, ovarian, and cervical cancers. Its main competitive advantages lie in its WHO-GMP/US-FDA/EMA regulatory approvals, world-class purity, and easy intravenous administration. The application surface is extensive, covering major anti-cancer protocols, ensuring a reliable and effective addition to oncological regimens.

Packaging, Sample Policy & Export Market Details

Packing & dispatch of Bevacizumab 400 mg/16 ml vials are meticulously managed for sterility and safety. Each single-use vial is drop-off ready in a protective Type I glass container with a secure rubber stopper. Shipped worldwide, Bevacizumab is often exported to international markets with guaranteed quality preservation. A sample policy may be available upon request. All orders are executed with precise cold-chain logistics to ensure product efficacy upon arrival.

FAQ's of Bevacizumab Concentrate For Solution For Infusion 400 M-G 16ML IN Single Use Vial:

Q: How should Bevacizumab Concentrate for Solution for Infusion 400 mg/16 ml be stored and handled?

A: Bevacizumab should be stored at 2C to 8C, protected from light. Do not freeze the vial. Ensure all handling and preparation is done under sterile conditions as it is a preservative-free, single-use infusion.

Q: What is the recommended method of administration for this product?

A: This medication must be administered as an intravenous infusion after proper dilution using 0.9% Sodium Chloride Injection, USP. It should not be mixed with glucose solutions. Always follow the physician's prescription guidelines.

Q: When is Bevacizumab typically prescribed for patients?

A: Bevacizumab is prescribed for adults diagnosed with metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, glioblastoma, ovarian cancer, and cervical cancer, depending on the doctor's assessment of suitability.

Q: Where does the product meet regulatory approval, and what does this imply?

A: The product is compliant with WHO-GMP, US-FDA, and EMA standards (as applicable), indicating it meets rigorous safety, quality, and efficacy benchmarks recognized in global healthcare markets.

Q: What makes Bevacizumab a competitive choice in oncology treatments?

A: Its world-class composition, proven efficacy, regulatory compliance, ease of administration, and wide-reaching export availability make Bevacizumab an optimal and valorous solution in contemporary cancer therapy.

Tell us about your requirement